A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice

Infection and Immunity

Volumn 78, Issue 8, 2010, Pages 3432-3442

  Wieser, Andreas ^a   Romann, Eva ^a   Magistro, Giuseppe ^a   Hoffmann, Christiane ^a   Nörenberg, Dominik ^a   Weinert, Kirsten ^a   Schubert, Sören ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; RECOMBINANT VACCINE; SECRETORY IMMUNOGLOBULIN; SUBUNIT VACCINE; BACTERIUM ANTIBODY; EPITOPE; ESCHERICHIA COLI PROTEIN; ESCHERICHIA COLI VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMBINANT GENE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE; MUCOSAL IMMUNITY; PERITONITIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; EPITOPES; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PERITONITIS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 77955296578     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00174-10     Document Type: Article

References (50)

1. Alteri, C. J., E. C. Hagan, K. E. Sivick, S. N. Smith, and H. L. Mobley. 2009. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 5:e1000586.
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
3. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 2005. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, NY.
4. Bielaszewska, M., U. Dobrindt, J. Gartner, I. Gallitz, J. Hacker, H. Karch, D. Muller, S. Schubert, S. M. Alexander, L. J. Sorsa, and J. Zdziarski. 2007. Aspects of genome plasticity in pathogenic Escherichia coli. Int. J. Med. Microbiol. 297:625-639.
5. Braun, V. 2005. Bacterial iron transport related to virulence. Contrib. Microbiol. 12:210-233.
6. Braun, V., M. Braun, and H. Killmann. 2000. Iron transport in Escherichia coli. Crystal structure of FhuA, an outer membrane iron and antibiotic transporter. Adv. Exp. Med. Biol. 485:33-43.
7. Brzuszkiewicz, E., H. Bruggemann, H. Liesegang, M. Emmerth, T. Olschlager, G. Nagy, K. Albermann, C. Wagner, C. Buchrieser, L. Emody, G. Gottschalk, J. Hacker, and U. Dobrindt. 2006. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc. Natl. Acad. Sci. U. S. A. 103:12879-12884.
8. Buchanan, S. K., B. S. Smith, L. Venkatramani, D. Xia, L. Esser, M. Palnitkar, R. Chakraborty, D. van der Helm, and J. Deisenhofer. 1999. Crystal structure of the outer membrane active transporter FepA from Escherichia coli. Nat. Struct. Biol. 6:56-63.
9. Campos, E. A., J. Namikoshi, S. Maeba, M. Yamamoto, M. Fukumoto, and H. Yamamoto. 2003. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant. J. Oral Sci. 45:25-31.
10. Dobrindt, U., F. Agerer, K. Michaelis, A. Janka, C. Buchrieser, M. Samuelson, C. Svanborg, G. Gottschalk, H. Karch, and J. Hacker. 2003. Analysis of genome plasticity in pathogenic and commensal Escherichia coli isolates by use of DNA arrays. J. Bacteriol. 185:1831-1840.
11. Durant, L., A. Metais, C. Soulama-Mouze, J. M. Genevard, X. Nassif, and S. Escaich. 2007. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect. Immun. 75:1916-1925. (Pubitemid 46559461)
12. Duriez, P., O. Clermont, S. Bonacorsi, E. Bingen, A. Chaventre, J. Elion, B. Picard, and E. Denamur. 2001. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations. Microbiology 147:1671-1676.
13. Fluit, A. C., J. Verhoef, and F. J. Schmitz. 2001. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur. J. Clin. Microbiol. Infect. Dis. 20:617-625.
14. Gao, H., Y. Yue, L. Hu, W. Xu, and S. Xiong. 2009. A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge. Vaccine 27:5313-5319.
15. Geginat, G., T. Nichterlein, M. Kretschmar, S. Schenk, H. Hof, M. Lalic- Multhaler, W. Goebel, and A. Bubert. 1999. Enhancement of the Listeria monocytogenes p60-specific CD4 and CD8 T cell memory by nonpathogenic Listeria innocua. J. Immunol. 162:4781-4789. (Pubitemid 29314880)
16. Gruber, A. R., R. Lorenz, S. H. Bernhart, R. Neubock, and I. L. Hofacker. 2008. The Vienna RNA websuite. Nucleic Acids Res. 36:W70-W74.
17. Gupta, K., T. M. Hooton, and W. E. Stamm. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135:41-50.
18. Gupta, K., T. M. Hooton, C. L. Wobbe, and W. E. Stamm. 1999. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int. J. Antimicrob. Agents 11:305-308.
19. Hagan, E. C., and H. L. Mobley. 2007. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect. Immun. 75:3941-3949.
20. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11:S45-S53.
21. Hood, L., M. Steinmetz, and B. Malissen. 1983. Genes of the major histocompatibility complex of the mouse. Annu. Rev. Immunol. 1:529-568.
22. Johnson, J. R., M. A. Kuskowski, A. Gajewski, S. Soto, J. P. Horcajada, M. T. Jimenez de Anta, and J. Vila. 2005. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J. Infect. Dis. 191:46-50.
23. Johnson, J. R., and T. A. Russo. 2002. Extraintestinal pathogenic Escherichia coli: "the other bad E. coli." J. Lab. Clin. Med. 139:155-162.
24. Johnson, J. R., and T. A. Russo. 2002. Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections. J. Infect. Dis. 186:859-864.
25. Jones-Carson, J., E. Balish, and D. T. Uehling. 1999. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J. Urol. 161: 338-341. (Pubitemid 29422358)
26. Kantele, A. M., N. V. Palkola, H. S. Arvilommi, and J. M. Kantele. 2008. Distinctive homing profile of pathogen-specific activated lymphocytes in human urinary tract infection. Clin. Immunol. 128:427-434.
27. Kurazono, H., M. Nakano, S. Yamamoto, O. Ogawa, K. Yuri, K. Nakata, M. Kimura, S. Makino, and G. B. Nair. 2003. Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island. Microbiol. Immunol. 47:797-802.
28. Kurazono, H., S. Yamamoto, M. Nakano, G. B. Nair, A. Terai, W. Chaicumpa, and H. Hayashi. 2000. Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein. Microb. Pathog. 28:183-189.
29. Langermann, S., R. Mollby, J. E. Burlein, S. R. Palaszynski, C. G. Auguste, A. DeFusco, R. Strouse, M. A. Schenerman, S. J. Hultgren, J. S. Pinkner, J. Winberg, L. Guldevall, M. Soderhall, K. Ishikawa, S. Normark, and S. Koenig. 2000. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181:774-778. (Pubitemid 30131859)
30. McBean, M., and S. Rajamani. 2001. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J. Infect. Dis. 183: 596-603.
31. Minino, A. M., R. N. Anderson, L. A. Fingerhut, M. A. Boudreault, and M. Warner. 2006. Deaths: injuries, 2002. Natl. Vital Stat. Rep. 54:1-124.
32. Mobley, H. L., D. M. Green, A. L. Trifillis, D. E. Johnson, G. R. Chippendale, C. V. Lockatell, B. D. Jones, and J. W. Warren. 1990. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect. Immun. 58:1281-1289.
33. Molder, T., M. Adojaan, K. Kaldma, M. Ustav, and R. Sikut. 2009. Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multicomponent fusion protein MultiHIV - study in domestic pigs. Vaccine 28:293-298.
34. O'Hanley, P., G. Lalonde, and G. Ji. 1991. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect. Immun. 59:1153-1161.
35. Reche, P. A., J. P. Glutting, and E. L. Reinherz. 2002. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol. 63:701-709.
36. Reigstad, C. S., S. J. Hultgren, and J. I. Gordon. 2007. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J. Biol. Chem. 282:21259-21267.
37. Roberts, J. A. 1999. Unconventional immunology and urinary tract infection. J. Urol. 161:3. (Pubitemid 29422277)
38. Russo, T. A., J. M. Beanan, R. Olson, S. A. Genagon, U. Macdonald, J. J. Cope, B. A. Davidson, B. Johnston, and J. R. Johnson. 2007. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 25:3859-3870.
39. Russo, T. A., and J. R. Johnson. 2003. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 5:449-456.
40. Russo, T. A., and J. R. Johnson. 2006. Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Expert Rev. Vaccines 5:45-54.
41. Russo, T. A., and J. R. Johnson. 2000. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J. Infect. Dis. 181:1753-1754.
42. Russo, T. A., C. D. McFadden, U. B. Carlino-MacDonald, J. M. Beanan, R. Olson, and G. E. Wilding. 2003. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect. Immun. 71:7164-7169.
43. Schmidhammer, S., R. Ramoner, L. Holtl, G. Bartsch, M. Thurnher, and C. Zelle-Rieser. 2002. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60:521-526.
44. Sette, A., M. Newman, B. Livingston, D. McKinney, J. Sidney, G. Ishioka, S. Tangri, J. Alexander, J. Fikes, and R. Chesnut. 2002. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 59:443-451. (Pubitemid 35034464)
45. Snyder, J. A., B. J. Haugen, E. L. Buckles, C. V. Lockatell, D. E. Johnson, M. S. Donnenberg, R. A. Welch, and H. L. Mobley. 2004. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect. Immun. 72:6373-6381.
46. Thumbikat, P., C. Waltenbaugh, A. J. Schaeffer, and D. J. Klumpp. 2006. Antigen-specific responses accelerate bacterial clearance in the bladder. J. Immunol. 176:3080-3086. (Pubitemid 43306970)
47. Vijh, S., and E. G. Pamer. 1997. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J. Immunol. 158:3366-3371.
48. Welch, R. A., V. Burland, G. Plunkett III, P. Redford, P. Roesch, D. Rasko, E. L. Buckles, S. R. Liou, A. Boutin, J. Hackett, D. Stroud, G. F. Mayhew, D. J. Rose, S. Zhou, D. C. Schwartz, N. T. Perna, H. L. Mobley, M. S. Donnenberg, and F. R. Blattner. 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 99:17020-17024.
49. York, I. A., S. C. Chang, T. Saric, J. A. Keys, J. M. Favreau, A. L. Goldberg, and K. L. Rock. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3:1177-1184.
50. Zahar, J. R., O. Lortholary, C. Martin, G. Potel, P. Plesiat, and P. Nordmann. 2009. Addressing the challenge of extended-spectrum beta-lactamases. Curr. Opin. Invest. Drugs 10:172-180.